News
Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has ...
RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback